Literature DB >> 16325873

Cure of antimony-unresponsive Indian post-kala-azar dermal leishmaniasis with oral miltefosine.

Shyam Sundar1, Kailash Kumar, Jaya Chakravarty, Dipti Agrawal, Shrinkhla Agrawal, Amit Chhabra, Vikram Singh.   

Abstract

We report the case of a patient with Indian post-kala-azar dermal leishmaniasis (PKDL) who failed to show any response to 2 months' treatment with sodium stibogluconate. Six months later he was treated with oral miltefosine on a compassionate basis as an off-label indication. Miltefosine was given 100mg daily in divided doses for an initial 8 weeks. Due to insufficient response, the treatment was extended up to a total of 12 weeks. The patient showed an excellent response to treatment, and after 12 months of follow-up there was complete healing of all cutaneous lesions. Oral miltefosine appears to be an important alternative for the treatment of PKDL in India and confirmatory studies in controlled clinical trials are needed.

Entities:  

Mesh：

Substances：

Year:  2005        PMID： 16325873     DOI： 10.1016/j.trstmh.2005.09.015

Source DB:  PubMed          Journal:  Trans R Soc Trop Med Hyg        ISSN： 0035-9203            Impact factor:   2.184


  8 in total

1.  Comparative transcript expression analysis of miltefosine-sensitive and miltefosine-resistant Leishmania donovani.

Authors:  Arpita Kulshrestha; Vanila Sharma; Ruchi Singh; Poonam Salotra
Journal:  Parasitol Res       Date:  2014-01-22       Impact factor: 2.289

2.  Economic consequences of post-kala-azar dermal leishmaniasis in a rural Bangladeshi community.

Authors:  Masayo Ozaki; Shamim Islam; Kazi Mizanur Rahman; Anisur Rahman; Stephen P Luby; Caryn Bern
Journal:  Am J Trop Med Hyg       Date:  2011-09       Impact factor: 2.345

3.  Drug susceptibility in Leishmania isolates following miltefosine treatment in cases of visceral leishmaniasis and post kala-azar dermal leishmaniasis.

Authors:  Vasundhra Bhandari; Arpita Kulshrestha; Deepak Kumar Deep; Olivia Stark; Vijay Kumar Prajapati; V Ramesh; Shyam Sundar; Gabriele Schonian; Jean Claude Dujardin; Poonam Salotra
Journal:  PLoS Negl Trop Dis       Date:  2012-05-22

4.  Evidence for involvement of Th17 type responses in post kala azar dermal leishmaniasis (PKDL).

Authors:  Gajendra Kumar Katara; Nasim Akhtar Ansari; Avninder Singh; V Ramesh; Poonam Salotra
Journal:  PLoS Negl Trop Dis       Date:  2012-06-19

Review 5.  Drug resistance in leishmaniasis: Newer developments.

Authors:  Sarita Mohapatra
Journal:  Trop Parasitol       Date:  2014-01

Review 6.  Immunotherapy and targeted therapies in treatment of visceral leishmaniasis: current status and future prospects.

Authors:  Om Prakash Singh; Shyam Sundar
Journal:  Front Immunol       Date:  2014-06-26       Impact factor: 7.561

7.  Therapeutic Modalities in Post Kala-azar Dermal Leishmaniasis: A Systematic Review of the Effectiveness and Safety of the Treatment Options.

Authors:  Adrija Datta; Indrashis Podder; Anupam Das; Amrita Sil; Nilay Kanti Das
Journal:  Indian J Dermatol       Date:  2021 Jan-Feb       Impact factor: 1.494

8.  Study on the safety and efficacy of miltefosine for the treatment of children and adolescents with post-kala-azar dermal leishmaniasis in Bangladesh, and an association of serum vitamin E and exposure to arsenic with post-kala-azar dermal leishmaniasis: an open clinical trial and case-control study protocol.

Authors:  D Mondal; M G Hasnain; M S Hossain; D Ghosh; P Ghosh; H Hossain; J Baker; R Nath; R Haque; G Matlashewski; S Hamano
Journal:  BMJ Open       Date:  2016-05-17       Impact factor: 2.692
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.